Skip to main content
. Author manuscript; available in PMC: 2018 Apr 6.
Published in final edited form as: Immunohorizons. 2017 Aug 15;1(6):101–108. doi: 10.4049/immunohorizons.1700024

FIGURE 6. PTX treatment abolishes IL-33–dependent monocyte migration to the lung extravascular space in response to OVA-IC.

FIGURE 6

IL-33−/− mice received α-OVA i.v. and either PBS or PTX i.p. OVA-AF647 sensitization with rIL-33 was delivered i.t. 24 h later. The mice were sacrificed 18 h after challenge. (A) Representative flow plots of Ag uptake (OVA-AF647) versus localization (i.v. CD45). (B) Percentage of OVA-AF647+ cells in the extravascular space. Data represent the mean ±SEM combined from three independent experiments with a total of at least 10 mice analyzed per group. ****p < 0.0001. ns, not significant.